By NewsDesk  @infectiousdiseasenews

In a follow-up on Norway’s pause in the use of the AstraZeneca vaccine, the Norwegian Institute of Public Health recommended stopping further use of the AstraZeneca vaccine (Vaxzevria) in the Coronavirus Immunisation Programme in Norway.

Image by Gerd Altmann from Pixabay

We now know significantly more about the association between the AstraZeneca vaccine and the rare but severe incidents with low platelet counts, blood clots and haemorrhagesthan when Norway decided to pause use of the AstraZeneca-vaccine in March,” says Geir BukholmDirector of the Division of Infection Control and Environmental Health at the Norwegian Institute of Public Health. 

Based on this knowledge, we come with a recommendation to remove the AstraZeneca vaccine from the Coronavirus Immunisation Programme in Norway,” says Bukholm. 

Having come a long way in vaccinating the oldest citizens, Norway has reduced the risk of death for many of those most at risk. Since most of the elderly have either been vaccinated, or soon will be, this means that continued use of the vaccine would mainly be among the under-65 years age group if we were to use this vaccine in Norway  

Calculations have been performed based on Norwegian data where the risk of dying from COVID-19 disease among the different age groups is compared with the risk of dying from the severe, but rare, condition with severe blood clots observed after AstraZeneca vaccination. 

“Since there are few people who die from COVID-19 in Norway, the risk of dying after vaccination with the AstraZeneca vaccine would be higher than the risk of dying from the disease, particularly for younger people,” says Bukholm. 

In addition, there is reason to assume that there is scepticism about using the AstraZeneca vaccine in Norway, and it is uncertain how many people would have accepted an offer of this vaccine now. 

People who have had the first dose of the AstraZeneca vaccine will be offered another coronavirus vaccine for their second dose. 

“We will come back with more specific information about when and how people who have had their first dose will get their second doseOne dose gives good protection against COVID-19 for at least 12 weeks,” says Bukholm.

CDC: Pause the use of the J&J COVID-19 vaccine until reviewed

AstraZeneca’s Vaxzevria: European officials find blood clots should be listed as very rare side effect

COVID-19 vaccine in Sweden: Nine out of ten say they will most certainly or probably will say yes

Sweden: 200 people have tested positive for COVID-19 post- two dose vaccine